Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers were also able to make the first-ever estimate of the level of antibodies needed for protection against HIV.
The Conference on Retroviruses and Opportunistic Infections in Seattle saw many important studies that are advancing the fight against HIV.
The insert contained the antiretrovirals tenofovir alafenamide, known as TAF, and Vitekta (elvitegravir).
In a recent small trial, researchers have been unable to detect viable virus in the tissues of two monkeys that received the treatment.
A new HIV vaccine prompts powerful antibody response in animals.
Researchers have devised a means of injecting an antiretroviral under the skin that hardens into a dissolvable and removable implant.
Beginning six months of treatment within two days following infection prevented viral rebound in at least some animals in a recent study.
Researchers were also able to make the first-ever estimate of the level of antibodies needed for protection against the virus.
Researchers have found a way of stabilizing a shape-shifting viral protein so as to promote a greater antibody response.
An antibody treatment plus an immune-stimulating agent delayed viral rebound in primates infected with HIV-like virus.
Today, with better understanding of the complex task at hand, cure researchers are investigating multiple avenues and taking the long view.
The “kick-and-kill” strategy—waking up latently infected immune cells so as to kill them—did not reduce participants’ viral DNA.
This disappointment highlights the challenge of translating animal research into human trials.
Published results have updated preliminary findings presented at a previous conference.
NIH researchers have prompted animals to develop broadly neutralizing antibodies against the virus; an early human trial is in the works.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.